Member Info for Early_Bird

"let's not forget YOLO's other investments: The TVPlayer and Simplestream businesses are both currently worth c£25m meaning YOLO's 5% stakes are worth £2.5m, plus Gfinity and AudioBoom stakes worth a combined further £0.5m, plus cash of c.£1m brings total to £4m. Add in the £1.4m in Electric Jukebox takes total to £5.4m or 1.2p. In other words YOLO trades at par to its underlying investments ie shares are strongly underpinned at 1.2p."

Orphan designation. Nice surprise. A reminder that Amyt has a portfolio of disruptive drugs. https://www.voxmarkets.co.uk/rns/announcement/25176261/?source=twitter

Sell up and move on, you really are very childish & irritating to genuine holders here. You will be doing yourself a favour and also us holders a favour. Plenty of opportunity in the markets & not every share appeals to everyone.... take your loss on the chin and move on. Strongly suspect you dont actually hold any here, is always mind baffling to me when people have nothing to do than troll BBs.... sad little lives they must have. Back to Amyt, the newsflow will do the talking here. Themanagement team cannot add any more as they are in concert parties with eachother owning over 30% between them.

big background buy?!

until we even get back to IPO price alone. Given how close P3 trials are away Id say, Equitrader you still have a nice opportunity to buy back in here before the traction happens. I cant see how you can be calling everyone else's posts apart from yours Pumping when this SP is clearly on the floor with exciting things just around the corner! We are getting excited (well I am), been holding this one for over 18 months back when it was Fastnet Oil & Gas let alone Fastnet equity.

Not the brightest spark in the box are we.... "Dummy" probably very apt actually when talking to you actually lol.... it means to put a trade through to see the live quote back from the market makers but then cancel it.

That's a standard comment, its a regulating committee granting approval not a business selling its product. Theyre hardly going to go "we think epislavan is the best thing since slice bread therefore we approve it and you should all go out and buy it" "Its benefits outweigh its risks" is how they pass comment to approve a product as its how they assess it. You realise less than 1 out of every 10 drugs that start Phase 1 trials ever get to be approved for marketing.

they haven't even heard of a "dummy trade" Do them all the time as its the only way to find out the actual live spread, gives an idea of how much MMs hold on the bid and ask.

Yes so you can clearly see statistically conclusive evidence that it works at speeding up wound healing above that of standard would healing care (Dressing with Octenilin® Wound Gel). "In both pivotal studies, Episalvan gel met the primary end-point and was significantly superior in both studies compared to standard dressing. In the first study, the mean time from surgery to wound closure was 17.1 days with standard of care treatment and 15.5 days when the wound was treated with Episalvan gel." Now that is for partial thickness wounds. Apply this to the epidermolysis bullosa (EB) market of which there is no other approved treatment (the key) and you have an absolute no brainer. £150m vs huge share of a £1.5b market. The fact that is already EU approved for PT wounds significantly de risks it when commencing P3 trials. The only other competitor studies require daily application vs every 3 to 4 days.... when a dressing takes 3 or 4 hours to change each day I wonder which treatment the patients will prefer to use.....

Indeed, there was only one sell today. IMO Pathetic attempt at keeping morale low as they clearly sold out and want cheaper entry, labelling every post as a Pump is pathetic.

notice how I said "potential" value. You are interpreting my comments in a way that you want to in order to please yourself it seems. Risk v reward. Downside risk v potential upside = compelling here. If you argue with that then I cant help you and you clearly cant help yourself.

*word "Pump" All about risk v reward as always for me. I see very little to no risk at current levels (given they have openly stated they could sell Epislavan for more than current MC tomorrow (which was £45m at the time) vs the 20 bag upside "potential" in the Medium term.

All facts are they not? Im beginning to think you just like the work "Pump"

$842m is 20 bags upside from current SP potential in the next quarter. Thats v compelling to me.

Ive been saying now is perfect entry timing for a while... Q4 is the quarter we are in now and the quarter I expect major traction here... Phase 3 trials are due to start in Q1 2017, so next quarter (ie not long)... our only other competitor treating the same rare disease that we are targetting got bought out for $842 as soon as it commenced its P3 trials. Those trials have now been delayed. Adding to that the competitor requires daily application where as Amryts Episalvan only requires application once every few days when they need to change their dressings. Given it takes some patients 3 or 4 hours to change their dressing having to apply the product every single day is totally impractical. Join the dots... it isnt rocket science, current market capital here v $842m.... we have big connections to the Pharma giant Shire. Traction will most certainly happen here in the next Q providing all on track which it is as otherwise they would have advised otherwise.

im getting quoted over 17p to sell? need to change your broker

Did you sell at the bottom per chance? Up 6% now... have some patience like the rest of us :)

hence the SP being up nearly 5%.... Perfect entry timing here IMO well done buyers.

to see the SP take a tumble today here. Just a case of being patient, RTO announcement in next few months could be quite exciting IMO. Of course nothing is guaranteed but the dots im joining look exciting.

Flirting with the 200dma (1264)... if this breaks then the rally is on. Think it will get broken this week.